Major UK retailers Marks and Spencer and John Lewis are scaling back their plus-size dress inventories. This change follows the growing popularity of weight-loss drugs such as Mounjaro.
The M&S size 22-24 inventory collapse
According to a study by the retail intelligence platform Edited, Marks and Spencer has seen a dramatic reduction in its largest clothing offerings. Specifically, the retailer's share of sizes 22-24 has plummeted from 2.2% to just 0.4% between 2022 and 2024.. This isn't just a minor adjustment; it represents a near-total removal of certain extreme plus-size categories from their current dress listings.
The broader plus-size category at Marks and Spencer is also experiencing a notable decline in availability. The retailer's share of sizes 18 and above has fallen from 34% to 27% over the same two-year period. This data suggests a strategic pivot away from the larger end of the size spectrum as the company adjusts its stock to meet perceived shifts in consumer body composition.
John Lewis's 3% dip in largest sizes
The trend is not isolated to Marks and Spencer, as John Lewis is also recalibrating its inventory to match changing consumer profiles. The report by Edited indicates that John Lewis has seen the share of its largest sizes decrease from 22.3% to 19.2%.
While the percentage drop at John Lewis is less precipitous than the collapse seen at Marks and Spencer, it still signals a clear move toward a smaller average customer size. Retailers are increasingly aligning their stock levels with the physical changes occurring within the UK population, likely to optimize inventory turnover and reduce unsold stock in shrinking demographics.
A retail response to the GLP-1 revolution
The fashion industry is witnessing a direct collision between pharmaceutical advancement and consumer demand. The rise of weight-loss medications, most notably Mounjaro, is fundamentally altering body composition across large segments of the population. As these drugs become more accessible, the demand for larger dress sizes is naturally softening.
This shift mirrors previous eras where health-driven cultural movements changed consumer habits , but the speed of the GLP-1 revolution is unprecedented. Unlike slow-moving dietary trends, the rapid physiological changes induced by these medications are forcing high street giants to make immediate, data-driven decisions about their supply chains to avoid carrying excess inventory.
The risk of overcorrecting for temporary weight loss
As retailers slash their plus-size ranges, several critical questions remain regarding the long-term stability of this strategy. First, how will Marks and Spencer and John Lewis respond if the use of weight-loss jabs fluctuates or if users experience weight regain?
There are also unanswered questions regarding the inclusivity and accuracy of this shift:
- Will the reduction in sizes 22-24 alienate a loyal customer base that may not be using medication?
- Is there a risk that retailers are reacting to a "lagging indicator" of body weight rather than a permanent shift?
- How will these brands maintain brand loyalty if their size inclusivity becomes a point of public criticism?
While the source reports that this trend is linked to the rising use of drugs like Mounjaro,it remains unverified whether these retailers are intentionally cutting stock to save costs or simply following a genuine, permanent drop in demand.
Comments 0